Search
Search Results
-
Pasireotide—a novel somatostatin receptor ligand after 20 years of use
Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5...
-
Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly
PurposePredicting resistance to first-generation Somatostatin Receptor Ligands (fg-SRL) in Acromegaly patients remains an ongong challenge....
-
Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
IntroductionPeople living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs),...
-
Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
BackgroundThe accumulation of 177 Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin...
-
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
PurposeWe present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR)...
-
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study
PurposeTo correlate somatostatin receptor (SSTR) and proliferative activity profile (SSTR2, SSTR5, Ki-67) at immunohistochemistry (IHC) with...
-
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PurposeThe need for an interval between the administration of long-acting Somatostatin Receptor Analogues (SSA) and the [ 68 Ga]Ga-DOTA-TATE PET has...
-
PET receptor imaging in breast cancer
Most of the breast cancers overexpress certain receptors which have a role in development and progression of the disease. Receptors are also target...
-
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry....
-
Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature
AimWe aimed to evaluate the prevalence of incidental 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings,...
-
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
PurposeThe aim of this retrospective analysis is to estimate the most appropriate single cycle and cumulative doses of 225 Ac-DOTATOC in patients...
-
Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly
Autophagy is an evolutionary conserved process for the self-degradation and recycling of cellular components in the cytoplasm. It is involved in both...
-
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs
PurposeTo evaluate the impact of pasireotide (PAS) therapy on hormonal and glycometabolic outcome in patients with acromegaly previously treated with...
-
Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
BackgroundAlthough most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR)...
-
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
IntroductionMedullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and...
-
Characterization of sporadic somatotropinomas with high GIP receptor expression
PurposeTo analyze the expression of glucose-dependent insulinotropic polypeptide receptor ( GIPR) in somatotropinomas specimens and compare clinical,...
-
A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
BackgroundSomatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for...
-
Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies
BackgroundSomatostatin receptors (SSTs) are widely co-expressed in pituitary tumors. SST 2 and SST 5 are the most represented SST subtypes....
-
Somatostatin-evoked Aβ catabolism in the brain: Mechanistic involvement of α-endosulfine-KATP channel pathway
Alzheimer’s disease (AD) is characterized by the deposition of amyloid β peptide (Aβ) in the brain. The neuropeptide somatostatin (SST) regulates Aβ...
